AGITG Trial News

The AGITG currently has eight  studies open to recruitment and ten  studies in follow up. The  table below details  the trials that  are currently  accruing patients. Recruited Target ACTICCA-1- Gallbladder carcinoma 2 50 ALT-GIST- GI Stromal Tumour 18 60 ASCOLT — Colorectal cancer 227 300 CONTROL NETs — NeuroEndocrine Tumour … Read More

August 16, 2017

4th Preceptorship in Colorectal Cancer

The 2016 AGITG Preceptorship in Colorectal Cancer was held on  Friday 11th and Saturday 12th November 2016 in Melbourne. 36 Senior trainees and Junior  consultants attended a  two day intensive learning course based on a complete review of literature to understand evolution of treatment for colorectal cancer in the adjuvant … Read More

December 6, 2016

InterAACT now open at several sites

InterAACT is an international, multicentre trial aiming to establish which chemotherapy regimen is more effective for rare inoperable advanced or metastatic anal cancer. By comparing two well-known and widely used combination chemotherapies (cisplatin plus 5-fluorouracil versus carboplatin plus weekly paclitaxel), we aim to demonstrate which one is more effective and … Read More

December 6, 2016

AGITG Preceptorship In Upper GI Cancer

Preceptorship in Upper GI Cancer – now open for applications Dates: Friday 5th & 6th May 2017 Venue: QT Hotel Surfers Paradise QLD Attention: Senior Trainees and Junior Consultants Convenor: A/Prof Eva Segelov Co-Convenor: Dr Lorraine Chantrill Participants from around Australia will be sponsored to attend. This two day intensive … Read More

November 16, 2016

INTEGRATE II recruits first patient

INTEGRATE II, an AGITG led Phase III clinical trial in gastro-oesophageal cancer has opened to recruitment.  Support for the final INTEGRATE II trial design was received from Bayer in November 2015.   INTEGRATE II is a Randomised Phase III Double-Blind Placebo-Controlled Study of regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) … Read More

November 14, 2016

Expert Meeting on Pancreatic Cancer

“Controversies in the management of patients with pancreatic cancer” On Sunday, 18 December a group of AGITG experts will be meeting in Singapore to discuss the controversies in the management of patients with pancreatic cancer. The meeting will be chaired by A/Professor Eva Segelov and attendees include: International Faculty: Prof … Read More

November 14, 2016

Consumer Advisory Panel: Call for EOI

The Australasian Gastro-Intestinal Trials Group (AGITG) is seeking expressions of interest from people affected by gastro-intestinal cancer (survivors/patients/carers/family) to join a Consumer Advisory Panel. Background Gastro-Intestinal cancers are those of the digestive system and include the oesophagus, stomach, liver, gall bladder, pancreas and bowel. The AGITG Consumer Advisory Panel was … Read More

October 26, 2016

AGITG ASM – Looking Back Moving Forward

This year marked the 25th anniversary of the Australasian Gastro-Intestinal Trials Group (AGITG) conducting and promoting clinical trials and related biological research in gastro-intestinal (GI) cancer. Looking back over 25 years and moving forward, the meeting presented information on the latest cutting edge research and evidence based treatments from leading … Read More

October 10, 2016

NABNEC is now open to recruitment

NABNEC, a randomised Phase II clinical trial recently funded by the NHMRC and supported by Specialised Therapeutics Australia (STA), is now open to patient recruitment. Currently sites open for this trial include: Royal North Shore Hospital, Westmead Hospital and Calvary Mater Newcastle Hospital. Sites still to be activated are located … Read More

October 7, 2016

QUASAR 2 Study published in Lancet Oncology

The QUASAR 2 clinical trial, a multicentre international study of capecitabine +/- bevacizumab as adjuvant treatment of colorectal cancer, was recently published in The Lancet Oncology. Chemotherapy given after surgery to patients with early-stage bowel cancer improves the disease cure rate. However, despite this the cancer often returns. 5 Fluorouracil … Read More

October 6, 2016